Pheochromocytomas Recruiting Phase 2 Trials for Cabozantinib (DB08875)

Also known as: Pheochromocytoma / Chromaffin cell neoplasm (morphologic abnormality) / Phaeochromocytoma / Pheochromocytoma (morphologic abnormality) / Phaeochromocytoma [Ambiguous]

IndicationStatusPhase
DBCOND0071316 (Pheochromocytomas)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04400474Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyTreatment